PO.TB04.01 · 肿瘤生物学
理解抑癌基因ARID1A在胃癌发生中的作用
Understanding the role of the tumor suppressor gene ARID1A in gastric cancer initiation
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:胃癌仍是全球癌症死亡的主要原因,并对美国服务不足的种族和族裔少数群体产生不成比例的影响。拉丁裔患者的发病率更高、结局更差,但基因组数据和患者来源模型仍然代表性不足。我们对拉丁裔胃癌(GC)队列进行的全外显子组测序(WES)显示,30%的肿瘤携带致病性ARID1A突变,与TCGA的频率相平行。ARID1A是SWI/SNF染色质重塑复合物的核心亚基,调控增强子活性和转录可及性。其缺失与预后不良和转移相关。我们假设ARID1A缺失通过染色质失调和转录重编程建立了一种早期的癌前状态。为验证这一点,我们开发了源自拉丁裔患者的长期胃类器官模型,以确定ARID1A缺失的最早细胞和分子后果。
方法:我们在拉丁裔患者来源的正常胃类器官中使用CRISPR/Cas9编辑生成了多个同基因胃类器官系,包括ARID1A/TP53双敲除(dKO)类器官和TP53敲除对照。类器官长期培养长达350天,并分析了早期(约150天)和晚期(约350天)的时间点。多组学表征包括H&E组织学、RNA测序、全外显子组测序和CUT&RUN分析。跨dKO、TP53 KO和野生型对照的比较被用于确定ARID1A缺失对早期肿瘤发生的影响。
结果:基因组编辑产生了ARID1A和TP53缺失,dKO类器官发展出进行性形态学异常,包括与对照相比增殖增加和独特的结构改变。RNA-seq分析显示了基因型特异性和时间依赖性的转录重编程。差异表达分析揭示了消化和铁转运通路的下调以及纤毛运动和纤毛发生的上调。全外显子组测序分析显示,14个变异在长期dKO克隆中共享,而每个克隆独立获得了1-6个额外的独特突变。受影响的基因涉及转录调控、细胞外基质重塑、囊泡运输和受体酪氨酸激酶信号传导。共享和克隆特异性变异的存在提示进行性基因组不稳定性,并支持由ARID1A/TP53双重缺失驱动的早期肿瘤演变。
结论:拉丁裔来源的胃类器官模型表明,ARID1A和TP53缺失协同驱动转录重编程、基因组不稳定性和早期发育异常进展。正在进行的CUT&RUN分析将确定染色质可及性的变化。这项工作为胃癌驱动因素提供了机制基础,并为精准预防策略提供了平台。
查看英文原文 English abstract
Introduction: Gastric cancer remains a major cause of global cancer mortality and disproportionately affects underserved racial and ethnic minority populations in the United States. Latino patients experience a higher incidence and worse outcomes, yet genomic data and patient-derived models remain underrepresented. Whole-exome sequencing (WES) of our Latino GC cohort showed that 30% of tumors harbor pathogenic ARID1A mutations, paralleling TCGA frequencies. ARID1A, a core subunit of the SWI/SNF chromatin-remodeling complex, regulates enhancer activity and transcriptional accessibility. Its loss is linked to poor prognosis and metastasis. We hypothesized that ARID1A loss establishes an early premalignant state through chromatin dysregulation and transcriptional reprogramming. To test this, we developed long-term gastric organoid models derived from Latino patients to define the earliest cellular and molecular consequences of ARID1A loss.
Methods: We generated multiple isogenic gastric organoid lines using CRISPR/Cas9 editing in Latino patient-derived normal gastric organoids, including ARID1A/TP53 double-knockout (dKO) organoids and TP53 knockout controls. Organoids were cultured long-term for up to 350 days, with early (~150-day) and late (~350-day) time points analyzed. Multi-omic characterization included H&E histology, RNA sequencing, whole exome sequencing, and CUT&RUN profiling. Comparisons across dKO, TP53 KO, and wild-type controls were used to define the effects of ARID1A loss on early tumorigenesis.
Results: Genome editing generated ARID1A and TP53 loss, and dKO organoids developed progressive morphological abnormalities, including increased proliferation and distinct architectural changes compared to controls. RNA-seq analyses showed genotype-specific and time-dependent transcriptional reprogramming. Differential expression analysis revealed downregulation of digestion and iron transport pathways and upregulation of cilium movement and ciliogenesis. Whole exome sequencing analysis showed fourteen variants were shared across long-term dKO clones, while each clone independently acquired 1-6 additional unique mutations. Affected genes were involved in transcriptional regulation, extracellular matrix remodeling, vesicle trafficking, and receptor tyrosine kinase signaling. The presence of shared and clone-specific variants suggests progressive genomic instability and supports early neoplastic evolution driven by dual ARID1A/TP53 loss.
Conclusion: Latino-derived gastric organoid models demonstrate that ARID1A and TP53 loss cooperatively drive transcriptional reprogramming, genomic instability, and early dysplastic progression. Ongoing CUT&RUN profiling will define chromatin accessibility changes. This work provides a mechanistic foundation for drivers of gastric cancer and a platform for precision prevention strategies.
利益披露 Disclosure
A. Morales Arana, None..
N. B. Halmai, None..
J. Diaz, None..
H. Zhang, None..
P. Lott, None..
L. Carvajal-Carmona, None.